Congenital lymphocytic choriomeningitis virus infection

General Neurology

Updated 03.29.2024
Released 10.22.2001
Expires For CME 03.29.2027

Congenital lymphocytic choriomeningitis virus infection

Authors: Daniel J Bonthius MD PhD, Richard McCormick MD

See Contributor Disclosures

Editor: Bernard L Maria MD

Congenital lymphocytic choriomeningitis virus infection

In This Article

Quick Link

Introduction

Overview

Lymphocytic choriomeningitis virus (LCMV) is a prevalent human pathogen that induces aseptic meningitis in children and adults. LCMV can also infect the fetus, where the virus targets the developing brain and induces substantial and permanent neuropathology. In this update, the authors discuss the importance of gestational age in determining the infectivity, pathology, and outcomes of congenital LCMV. The authors describe ways in which both the fetus and the placenta change over the course of gestation to alter the teratogenic impact of LCMV. In addition, the authors discuss the differential diagnosis of congenital LCMV, including both infectious and noninfectious disorders that can mimic this important prenatal infection.

Key points

	• Lymphocytic choriomeningitis virus (LCMV) is endemic in wild mice throughout the world.
	• Humans can become infected with LCMV through contact with the secretions or excretions of infected mice.
	• In postnatal humans, LCMV typically produces a brief febrile illness that often includes aseptic meningitis.
	• LCMV can cross the placenta, where it preferentially infects the human fetal brain and retina and causes substantial permanent injury.
	• Much of the pathology induced by LCMV infection is immune-mediated.
	• Any child with a suspected congenital infection, especially those with microcephaly and periventricular calcifications, should undergo serologic testing for LCMV.

Historical note and terminology

Lymphocytic choriomeningitis virus is a prevalent human pathogen and an important cause of neurologic birth defects in humans. Congenital LCMV infection is under-recognized by pediatricians and neurologists and is probably responsible for far more cases of congenital brain and retinal injury than has previously been realized (35).

LCMV was first isolated in 1933 by Armstrong and Lillie from the cerebrospinal fluid of a woman who was thought to have St. Louis encephalitis. This patient had initially presented with general malaise, but her condition progressively worsened, and she died. The virus isolated from her cerebrospinal fluid was passaged five times through monkeys and, with each passage, produced a disease resembling St. Louis encephalitis. However, on the sixth passage, the virus was inoculated into a monkey that was immune to St. Louis encephalitis, yet still produced the disease. Armstrong and Lillie isolated this new infectious agent and named it lymphocytic choriomeningitis virus, for the pathologic changes that it induced in the choroid plexus and meninges of infected mice and monkeys (03).

The virus was subsequently isolated from cerebrospinal fluid of patients with aseptic meningitis, and it was soon firmly established that LCMV was an important etiologic agent of aseptic meningitis in man. Subsequent clinical and etiologic studies identified LCMV as one of the most frequent infectious causes of aseptic meningitis in humans (58). The first recognized case of congenital infection with LCMV was reported in England in 1955 (48). In the decades that followed, multiple cases of congenital LCMV infection were reported throughout Europe. Although LCMV has been recognized as an important cause of aseptic meningitis in the United States for decades, the first cases of congenital LCMV infection were not reported in this country until 1993 (06; 50).

Although LCMV was discovered in 1933, the virus was not classified until the late 1960s, when it was placed in the newly formed Arenaviridae family of viruses. The arenaviruses are enveloped single-stranded RNA viruses. The arena group of viruses gains their name from arenosus, the Latin word for "sandy," on the basis of the fine granularities observed within the virion on ultrathin electron microscopic sections (21).

Like most arenaviruses, LCMV utilizes rodents as its principal reservoir. The only arenaviruses with nonrodent reservoirs are the Tacaribe virus, which infects bats, and an identified arenavirus found in boid snakes (10).

Mus musculus, the common house mouse, is both the natural host and reservoir for LCMV, which is transferred vertically from one generation to the next within the mouse population by intrauterine infection. Hamsters are also competent reservoirs. Although they may be heavily infected with LCMV, rodents that acquire the virus transplacentally often remain asymptomatic because the virus is not cytolytic and because congenital infection in rodents provides them with immunological tolerance for the virus. Mice and hamsters infected with LCMV shed the virus in large quantities in nasal secretions, saliva, milk, semen, urine, and feces throughout their lives.

Postnatal humans typically acquire LCMV by direct contact with fomites contaminated with infectious virus or by inhalation of aerosolized virus. Postnatal humans can also acquire the virus via organ transplantation (38; 24). Congenital LCMV infection occurs when a woman acquires LCMV during pregnancy. The virus is passed to the fetus transplacentally, presumably during maternal viremia. The virus may also be acquired by the fetus during the intrapartum period (48).

Clinical manifestations

Presentation and course

	• The clinical manifestations of LCMV infection depend on whether the infection is acquired postnatally or prenatally.
	• In postnatal (acquired) LCMV infections, the symptoms are typically relatively mild and reversible, and they consist of fever, malaise, and headache.
	• In prenatal (congenital) LCMV infections, the effects are often much more serious and include microcephaly, periventricular calcifications, and retinitis.
	• Neuroimaging in congenital LCMV infection may reveal a variety of abnormalities, including microencephaly, periventricular calcifications, cerebellar hypoplasia, neuronal migration disturbances, and encephalomalacia.
	• The prognosis in congenital LCMV infection is generally poor and includes cognitive impairment, epilepsy, cerebral palsy, and blindness.

The clinical manifestations of lymphocytic choriomeningitis virus infection depend strongly on the developmental stage of the human at the time of infection (14). In particular, clinical signs and symptoms depend on whether the infection occurs during the prenatal period or during postnatal life. Congenital infection of a human with LCMV involves both the postnatal infection of a pregnant woman and the prenatal infection of a fetus. History of a maternal illness during pregnancy consistent with LCMV infection can aid in the diagnosis of congenital LCMV infection. Thus, although the focus of this chapter is congenital LCMV infection, the clinical manifestations of both postnatal and prenatal infection will be discussed.

Acquired (postnatal) LCMV infection. LCMV infection during postnatal life (during childhood or adulthood) typically manifests itself as a brief febrile illness from which the patient fully recovers (39). Classic LCMV infection is a biphasic disease in which the initial symptoms include myalgia, fever, malaise, headache, anorexia, nausea, and vomiting. Defervescence and abatement of constitutional symptoms ensues, often followed by a second phase, consisting of central nervous system disease. The symptoms of this CNS phase of the disease are usually those of aseptic meningitis, including headache, nuchal rigidity, fever, vomiting, and photophobia. The entire course of the disease is usually only 1 to 3 weeks (43).

Laboratory abnormalities frequently observed during the initial febrile phase include thrombocytopenia, leukopenia, and mild elevations of liver enzymes. Infiltrates may appear on chest radiographs. The hallmark laboratory abnormality during the second CNS phase of the illness is a CSF pleocytosis. The CSF may contain hundreds to thousands of white blood cells, most of which are lymphocytes. CSF eosinophilia has also been reported (26). Hypoglycorrhachia and mild elevations of CSF protein can also occur.

The clinical spectrum of acquired LCMV infection is broad. In as many as one-third of postnatal infections, the disease is asymptomatic. Others develop extraneural disease that extends beyond the usual symptoms and may include orchitis, pneumonitis, myocarditis, parotitis, dermatitis, and pharyngitis (54). In other patients, the CNS disease may be considerably more severe than usual and may include transverse myelitis, Guillain-Barré syndrome, hydrocephalus, and encephalitis. Although recovery is usually complete, fatalities from acquired LCMV infection occasionally occur (58).

Infections acquired by solid organ transplantation are always severe. Recipients of infected organs typically develop fever, leukopenia, and lethargy several weeks post-transplantation and then rapidly progress to multi-organ system failure and shock. Most of these cases are fatal (38; 24).

Congenital LCMV infection. Infection of the human fetus can induce spontaneous abortion and death of the fetus (09). Among those fetuses that survive, the two cardinal signs of congenital LCMV infection are (1) vision impairment and (2) brain dysfunction (08).

The vision impairment is due principally to chorioretinitis and the formation of chorioretinal scars. The most common location of the chorioretinal scarring is in the periphery of the fundus, whereas scarring of the macula is somewhat less common (02). The chorioretinopathy is usually bilateral. Other ocular abnormalities reported in congenital LCMV infection include optic atrophy, nystagmus, vitreitis, strabismus, microphthalmos, and cataract (07).

Although the vision impairment induced by congenital LCMV infection is often severe, it is the effect of LCMV on the developing fetal brain that causes the greatest disability. Prenatal infection with LCMV often leads to either macrocephaly or microcephaly. The macrocephaly observed in infants with congenital LCMV is almost invariably due to a noncommunicating hydrocephalus. The microcephaly accompanying congenital LCMV infection is due to a virus-induced failure of brain growth. Periventricular calcifications are also cardinal features of congenital LCMV infection (82; 19; 31).

Although hydrocephalus, microencephaly, and periventricular calcifications are most commonly observed, other forms of neuropathology, alone or in combination, can also occur.

Pathologic changes in congenital LCMV infection

These images, obtained from children with serologically confirmed congenital LCMV infection, demonstrate that congenital LCMV infection can affect a variety of brain regions and lead to a diverse set of pathologic changes. Each of...

These include periventricular cysts, porencephalic cysts, encephalomalacia, intraparenchymal calcifications, cerebellar hypoplasia, and neuronal migration disturbances (19).

Brain function in children with congenital LCMV infection is often severely and permanently impaired. Mental retardation, cerebral palsy, ataxia, seizure disorders, and decreased visual acuity are common neurologic sequelae (51). However, one study has demonstrated that the outcomes of children with congenital LCMV infection may be broad (19). All children with the combination of microencephaly and periventricular calcifications are profoundly neurologically impaired. Spastic quadriparesis, profound mental retardation, blindness, and medically refractory epilepsy are typical of this group. But other children with congenital LCMV infection, who do not have the combination of microencephaly and periventricular calcifications, typically have a more favorable outcome with less severe motor, mental, and vision impairments. Children with isolated cerebellar hypoplasia are often ataxic but have only mild or moderate mental retardation and vision loss (19). The differences in outcome among children with congenital LCMV infection are likely due to differences in the gestational timing of infection (16).

Unlike many other congenital infections, LCMV does not typically induce systemic manifestations. Birth weight is typically appropriate for gestational age. Skin rashes and thrombocytopenia, which are common in several other prominent congenital infections, are unusual in congenital LCMV infection. Hepatosplenomegaly is only rarely observed, and serum liver enzyme levels are usually normal. Auditory deficits are unusual.

Prognosis and complications

Most patients who acquire LCMV postnatally have a full recovery with no long-term sequelae. However, occasionally, LCMV infection induces persistent problems. The ventriculitis and meningitis induced by LCMV sometimes leads to the complication of noncommunicating hydrocephalus, thus, necessitating placement of a permanent ventriculo-peritoneal shunt (50). In addition, some adult patients with LCMV have lingering symptoms, including headaches, arthralgias, and neuropsychological problems that may persist for more than a year after the acute symptoms of infection have resolved (71).

The prognosis for children with congenital LCMV infection is generally poor. A meta-analysis of all reported cases of congenital LCMV infection revealed a mortality rate of 35% by 21 months of age (82). Of those that survive, most have severe neurodevelopmental disorders, including microcephaly, poor somatic growth, profound vision impairment, severe seizure disorders, spastic weakness, and substantial mental retardation (51). However, some of these children have only moderate neurologic and mental handicaps, and a few have been described as having a normal outcome (16). Hearing is relatively spared in children with congenital LCMV infection, and developmental regression is virtually absent.

Complications in children with congenital LCMV infection are nonspecific and consist of the medical problems that commonly arise in scenarios involving ventriculoperitoneal shunts, severe seizure disorders, and static encephalopathy. These complications include shunt failure or infection, aspiration pneumonia, injuries from falls, and joint contractures.

Clinical vignette

The patient was the 3486 g (appropriate for gestational age) product of a 41-week gestation born to a 25-year-old gravida 3 para two Caucasian married woman. The pregnancy was uncomplicated until the third trimester, when the mother experienced a “flu-like” illness with symptoms that included fever, headache, malaise, nausea, and vomiting. The illness was monophasic, self-limited, and ended after 3 to 4 days. Several weeks later, a routine ultrasound was performed that revealed fetal ventriculomegaly. Weekly ultrasounds were performed for the duration of the pregnancy and showed stable ventriculomegaly.

The male infant was delivered vaginally without complications. Apgar scores were 6 at 1 minute and 8 at 5 minutes. The physical examination at birth was remarkable for plagiocephaly, with a protuberance of the right parieto-occipital region. The anterior fontanelle was open, soft, and flat. The fronto-occipital head circumference was 34.0 cm (50th percentile for gestational age). The infant appeared healthy and was transported to the newborn intensive care unit because of the prenatally observed ventriculomegaly. In the NICU, the infant was irritable but alert and had moderately increased muscle tone in all four extremities but had no contractures. The remainder of the physical examination was unremarkable. In particular, no dysmorphic features were present (except for the plagiocephaly), nor was there any rash, heart murmur, or hepatosplenomegaly.

A head CT scan revealed bilateral periventricular mineralizations and an area of severe encephalomalacia adjacent to the posterior horn of the right lateral ventricle.

Congenital LCMV infection in neonate (CT)

Head CT scan obtained from a patient with congenital LCMV infection at 2 days of age. The head CT scan is markedly abnormal and reveals bilateral periventricular mineralizations (arrows) and encephalomalacia with severe cortical t...

Cerebrospinal fluid examination revealed 0 red blood cells/µl, 4 white blood cells/µl (2 lymphocytes and 2 histiocytes), a protein content of 122 mg/dl, and a glucose content of 69 mg/dl. Blood glucose content was 85 mg/dl. Complete blood count and white blood cell differential were unremarkable.

Studies for infectious pathogens obtained during the first two weeks of life included a negative urine culture for cytomegalovirus and negative serologic studies for Toxoplasma gondii, herpes simplex virus, rubella, and Treponema pallidum (syphilis). Serologic studies for LCMV, assayed by the state hygienic laboratory using a complement fixation method and by the Centers for Disease Control and Prevention using an enzyme-linked immunosorbent assay, were consistent with intrauterine infection with LCMV. Table 1 shows the child's serologic titers for LCMV at various ages.

Table 1. Titers for Lymphocytic Choriomeningitis Virus Infection

Age	Method	IgM	IgG
2 weeks 2 weeks 11 months	Complement fixation ELISA ELISA	1:400 1:100 negative	1:1600 1:6400 1:1600

At 3 months of age, the patient’s parents reported that he would not fixate or visually follow and that he was not yet rolling over. Examination confirmed the lack of visually directed behavior. His pupils reacted only minimally to light, and he had bilateral exotropia. Funduscopy revealed marked chorioretinal scarring bilaterally.

Further physical examination at this same age revealed that the child had poor head control and that the diffuse hypertonia, which had been evident at birth, had worsened. The child had “cortical” thumbs bilaterally and abnormally brisk muscle stretch reflexes in all four extremities. In addition, the head circumference had increased out of proportion to body growth. Repeat head CT scan revealed worsened ventriculomegaly, which necessitated placement of a ventriculoperitoneal shunt.

At 6 months of age, the child began having seizures of several varieties. One type of seizure consisted of behavioral arrest, staring, and eyelid fluttering, with duration of 30 to 90 seconds. The second type consisted of generalized tonic-clonic activity, with duration of several minutes. EEG was abnormal interictally, both during sleep and while awake, with multifocal sharp and spike-waves. MRI scan of the brain was markedly abnormal with bilateral colpocephaly, extensive regions of cerebrocortical encephalomalacia, and cerebellar hypoplasia.

Congenital LCMV infection in infant (MRI)

Brain MRI scan in a patient with congenital LCMV infection at 6 months of age. (A) The coronal FLAIR image reveals colpocephaly (asterisk) and severe encephalomalacia with cortical thinning (arrowhead). (B) The midline sagittal T1...

The seizures were reduced in frequency with phenobarbital.

At 11 months of age, the child was seen for follow-up in the child neurology clinic. His mother reported that the child had multiple seizure types, each of which occurred several times per week. The seizures were improved, but not eliminated, by treatment with phenobarbital. His developmental progress was very slow. On examination, he continued to have plagiocephaly, was diffusely hypertonic and hyperreflexic, and he showed no visually directed behavior. Serologic studies were consistent with a past infection with LCMV.

At five years of age, the child had severe cognitive, motor, and vision impairment. He had no use of language. He was non-ambulatory but could maneuver around a room by crawling. He had severe vision deficits and would respond behaviorally to bright lights only. He continued to have occasional seizures, but these were relatively well controlled on carbamazepine monotherapy.

Biological basis

Etiology and pathogenesis

	• LCMV can cross the placenta, where it infects the fetus and causes congenital LCMV infection.
	• In the fetus, LCMV has a strong neurotropism. As a result, most of the pathology in congenital LCMV infection occurs within the brain and retina.
	• Glial cells are the major cell type in which LCMV replicates and spreads throughout the developing brain.
	• Much of the pathology induced by congenital LCMV infection is immune-mediated and is driven by CD8+ lymphocytes.
	• Neuronal migration disturbances are due to LCMV-induced disruption of radial glial cells.
	• LCMV can persist in neurons and induce long-term changes in neuronal gene expression, with behavioral consequences.

Congenital LCMV infection is due to the transplacental infection of the fetus with the arenavirus, lymphocytic choriomeningitis. In some cases, the infection may also be acquired by the fetus during the intrapartum period, presumably by exposure of the fetus to maternal blood or vaginal secretions during maternal viremia.

The mechanism by which LCMV damages the fetal human brain is unknown. LCMV is not a cytolytic virus in most cell types, including neurons. Thus, unlike herpes and several other pathogens that directly induce brain damage by killing host neurons, LCMV teratogenesis must have some other underlying pathogenesis.

The pathogenic mechanisms of LCMV have been studied extensively in the acutely infected adult mouse. Following intracranial inoculation of the adult mouse, LCMV replicates to high titers in the choroid plexus and meninges within several days. Viral antigen within these tissues becomes the target of an acute mononuclear cell infiltration driven by antigen-specific, CD8+ T-lymphocytes.

LCMV infection in mouse brain

In the adult mouse brain, LCMV selectively infects the leptomeninges, choroid plexus, and ventricular ependymal lining, where the virus induces a lymphocytic infiltration. Fifty-micrometer-thick section through the tissues surroun...

During the acute infection, LCMV replication is limited to the meningeal and ependymal membranes of the brain and to the choroid plexus, and very little virus penetrates into the brain parenchyma. Acutely infected adult mice typically die between 6 and 9 days post-inoculation as a result of this T-cell driven acute meningitis. Evidence that the disease is immune-mediated lies in the findings that generalized immunosuppression or specific deletion of T-cell subsets blocks onset of the acute disease. In these immunocompromised adult mice, viral clearance is delayed or blocked, and a persistent infection results, but the mice survive and remain free of acute disease (21).

As is true of virtually all infections, the genetic background of the host is an important factor in LCMV infectivity, immune response, and mortality (29). Among three common mice strains with different major histocompatibility complex (MHC) haplotypes, there were marked differences in CD8+ T-cell activation, viral load, and immunopathology 30 days after infection. Likewise, genetic differences in humans likely underlie the range in LCMV disease.

In an effort to understand the high susceptibility of fetuses and neonates to CNS infections, studies using LCMV-infected mice have investigated the mechanisms by which pathogens breach the brain’s protective barriers (44). The structural barrier of CNS border tissues is similar in the developing and adult CNS. However, there are stark differences in the make-up of dural immune cells between these two populations. In particular, in response to LCMV infection, major histocompatibility complex class II (MHCII)hi macrophages are enriched in the adult CNS, whereas they are rare in the developing CNS. These MHCIIhi macrophages are specialized to produce antiviral molecules and chemokines. Their relative absence in the developing CNS likely underlies the greater susceptibility of the developing CNS to infection with LCMV and other pathogens (44).

Although the adaptive immune response (and, in particular, T-cells) plays a critical role in LCMV-induced disease, the innate immune system plays a crucial role as well. In particular, type 1 interferons (IFN-1) can substantially worsen the effects of LCMV infection (81). IFN-1 is a cytokine that is produced and secreted by many cell types in response to pathogens. It facilitates communication among cells and can trigger protective defenses of the adaptive immune system. IFN-1 has long been thought to protect the host against viral infections due to its antiviral and immune-stimulating effects. However, studies have shown that IFN-1 can substantially worsen the vascular pathology and immune disruption of LCMV infection and can impair clearance of the virus. Conversely, blockade of IFN-1 using an IFN-1 receptor neutralizing antibody restored vascular health and the integrity of the immune system and facilitated clearance of the virus (76). Thus, IFN-1 can harm the host during LCMV infection. The results suggest that compounds or signaling pathways that interfere with IFN-1 signaling may have a therapeutic effect in LCMV infections.

The presence of other viral pathogens can also alter IFN-1 expression and can, thus, interact with LCMV. For example, ectromelia virus (ECTV) is usually lethal in mice, due to blockade of IFN-1. However, coinfection with LCMV rescues the mice via the LCMV-induced upregulation of IFN-1. Conversely, the ECTV infection partially suppresses the IFN-1 production induced by LCMV, thus, leading to diminished CD8 T-cell responses by LCMV. These findings demonstrate that coinfection of LCMV with other viruses, which is an event that likely occurs commonly in nature, can substantially alter the outcome of both infections (55). The immune-mediated mechanisms of disease observed in adult mice with LCMV probably also contribute to some of the pathology induced in the human fetus infected with the virus. In particular, the hydrocephalus commonly observed in children with congenital LCMV is likely due to ependymal inflammation within the ventricular system, particularly at the cerebral aqueduct, with a secondary blockage of CSF egress.

Mice may also serve as an excellent model for studying LCMV- induced chorioretinitis. In contrast to intracerebral inoculation, intraocular injection of adult mice with LCMV is not lethal, but instead leads to inflammation of the choroid and retina, resulting in disorganized retinal cytoarchitecture, abnormal electrophysiological responses, and vision loss, similar to that observed in children congenitally exposed to LCMV. This pathological process is primarily mediated by the host immune system and can be prevented by pharmacological, immunological, or genetic inhibition of the immune system. Successive adoptive transfer of primed CD8 T-cells into these immunocompromised animals recapitulates the disease, thus demonstrating that CD8 cells are solely responsible for induced retinopathy, with negligible contribution from CD4 cells (84).

Adult mice that were infected as neonates with LCMV have persistent infection with the virus, accompanied by long-term learning and behavior issues. Studies have shown that these behavioral effects are due, at least in part, to virus-induced interference with the production of neuroblasts in the normally mitotically active dentate gyrus and subventricular zone of adult mice. The chronic upregulation of chemokines, induced by the persistent infection, appears to underlie these defects in neurogenesis (74).

The adult mouse is probably not the best animal model system for the study of congenital LCMV infection. However, intracerebral inoculation of the neonatal rat with LCMV is a superb model system of human congenital LCMV infection. Inoculation of the neonatal rat with LCMV results in a distinct pattern of infection in which specific brain regions are consistently and heavily infected with the virus, whereas other brain regions are entirely spared (60; 59). Importantly, unlike infection of the adult mouse, LCMV infection of the neonatal rat results in the infection of multiple populations of neurons as well as infection of the meninges and choroid plexus (18).

Not all neuronal populations of the developing brain are vulnerable to LCMV infection. Indeed, the neonatal rat model has shown that the only brain regions vulnerable to neuronal infection are those in which neurogenesis is occurring (17). The converse is also true: all brain regions in which neurogenesis is occurring are vulnerable to LCMV infection.

LCMV target regions in developing brain

Within the developing brain, LCMV specifically targets regions containing mitotically active neuronal precursors. [A] During the early postnatal period in the rat, neurogenesis continues in 4 brain regions, which include the cereb...

This one-to-one correspondence between infectability and neurogenesis suggests that the metabolic machinery present within mitotically active neurons facilitates the propagation and survival of LCMV (15; 16). The periventricular calcifications commonly observed in humans with congenital LCMV infection probably reflect the infection and death of mitotically active neuronal precursors of the subependymal periventricular region.

Vulnerability of periventricular region to LCMV infection

The periventricular region is selectively vulnerable to LCMV infection and pathology in the human fetus and in the developing rat. [A] This head CT scan from an infant with congenital LCMV infection reveals microencephaly and peri...

Neuronal migration defects are often present in children congenitally infected with LCMV. Likewise, in the developing rat brain, LCMV infection disrupts the migration of recently generated neurons.

Disruption of neuronal migration in LCMV-infected brain

Congenital LCMV infection disrupts neuronal migration in the developing human brain and in the rat model. [A] MRI scan of a 3-year-old child with congenital LCMV infection. The MRI scan demonstrates microencephaly and a deficit of...

A study examining the effect of LCMV on cerebellar development in the neonatal rat has shed considerable light on the pathogenesis of congenital LCMV infection (46). In particular, when the neonatal rat is infected with LCMV, three separate forms of pathology occur in the developing cerebellum: (1) destructive lesions that lead to porencephalic cysts, (2) cerebellar hypoplasia that leads to regional or global reductions in cerebellar size, and (3) neuronal migration disturbances that lead to permanently ectopically located granule neurons. To determine which of these forms of pathology are immune-mediated and driven by T-lymphocytes, the effects of infection were compared in wild type rats and in congenitally athymic rats, which lack T-cells. If a form of pathology is immune-mediated and driven by T-lymphocytes, then that pathology will be absent in congenitally athymic rats. The study showed that the destructive lesions and the neuronal migration disturbances, which are very prominent in the wild type rats, fail to occur in the athymic rats. In contrast, the cerebellar hypoplasia occurs in both wild type and athymic rats. Thus, the destructive lesions and the neuronal migration disturbances are immune-mediated, whereas the cerebellar hypoplasia is not immune-mediated and is likely due to virus-induced interference with cellular mitosis.

The rat model of congenital LCMV infection has shown that the effect of LCMV on the developing brain depends critically on the developmental stage of the host at the time of infection (16). The cellular targets of infection, the peak viral titers in tissues, and the nature and severity of neuropathology all depend strongly on age of the developing host. For example, neurons of the cerebral cortex are highly infectible on postnatal day 1 but are not infectible just 3 days later, on postnatal day 4.

Cellular targets of LCMV within the developing brain depend strongly on host age

Shown here are sections through the cerebral cortex of rat pups infected with LCMV on a variety of postnatal ages and immunohistochemically stained for LCMV antigens. [A] and [B] Infection on PD 1 leads to a widespread and heavy i...

Within the developing brain, infectability and pathology can change dramatically over the course of only a few days. All of the various neuropathologic changes evident in humans with congenital LCMV infection can be recapitulated in the rat model by infecting developing rats at different developmental stages. These findings suggest that the variability in outcome among children with congenital LCMV infection is due to differences in the gestational timing of infection (17).

Further evidence that the gestational timing of infection is a critically important variable is derived from a study examining LCMV in placental tissues. Enninga and Theiler exposed first trimester and third trimester explants of human placentas to LCMV in vitro (36). They found that LCMV could infect and replicate in first trimester placentas, but not in third trimester placentas. In addition, they found that LCMV induced no innate immune response in first trimester placentas, but did induce a robust innate immune response with high expression levels of proinflammatory and antiviral cytokines in third trimester placentas. These findings suggest that, later in gestation, the placenta can exert protective effects against LCMV infection that are not present earlier in gestation. Thus, there is strong evidence that both the fetus and the placenta evolve over the course of gestation in ways that alter the outcome of LCMV infection (16; 36).

Glial cells play critical roles in the propagation and spread of LCMV within the developing brain. Astrocytes and Bergmann glial cells are the initial cells of the brain parenchyma infected with LCMV. Furthermore, these glial populations are the principal site of LCMV propagation and are the conduit by which the virus spreads throughout the brain and into vulnerable neuronal populations (15).

Glial cells may also play an important role in LCMV-induced inflammation. Astroglia are the dominant expressors of certain chemokines and their ligand/receptors (eg, CXCR 10 and IFN), and these same astroglia-expressed molecules play critical roles in controlling the pattern of T cell infiltration. Thus, astrocytes may be a major agent through which the virus spreads through the brain and a principal effector of the cytokine-chemokine cascade elicited by the infection (28).

LCMV is a highly neurotropic virus, both in the human and in the neonatal rat. The mechanism underlying this tropism for certain tissues and cell types remains unknown but may be due to the presence of a "receptor" for the virus. Certain cells may express a molecule on their external surfaces to which LCMV may become anchored in preparation for viral entry. A particular membrane glycoprotein, referred to as "alpha-dystroglycan," has been identified as a "receptor" for LCMV on cultured astrocytes (22). Cultured cells containing a null mutation for alpha-dystroglycan are not susceptible to LCMV infection, whereas cells in which the gene for alpha-dystroglycan is replaced are susceptible (70).

Alpha-dystroglycan is part of the dystroglycan complex, a set of proteins on the cell surface that spans the cell membrane and links molecules of the extracellular matrix, including laminin, agrin, and neurexin, with the internal actin-cytoskeletal machinery. The dystroglycan complex stabilizes the cell membrane and may also transmit signals from the extracellular environment to internal cellular machinery. When LCMV binds to alpha-dystroglycan, the virus displaces components of the extracellular space that normally bind to the dystroglycan complex. As a result, LCMV may produce some of its pathologic effects by disrupting dystroglycan function. For example, because the interactions of dystroglycan with extracellular laminin are important for membrane stability, disruption of these interactions by LCMV may increase the fragility of the cell membrane and contribute to the death or dysfunction of the affected cell (64).

Various strains of LCMV differ in their avidity for alpha-dystroglycan (72) and can be divided into high affinity and low affinity groups (70). In mice, the high affinity group depends on alpha-dystroglycan for cell entry, localizes to the spleen’s white pulp, dampens the cytotoxic T-lymphocyte response, and induces a persistent infection. In contrast, the low affinity group does not depend on alpha-dystroglycan for cell entry, localizes to the spleen’s red pulp, induces a strong cytotoxic T-lymphocyte response, and leads to viral clearance (70). Thus, the low and high affinity LCMV strains have different cellular targets and cause different diseases.

Interestingly, the presence of alpha-dystroglycan on a cell surface is neither necessary nor sufficient for infection, even among those LCMV strains that have a high affinity for alpha-dystroglycan. A study has shown that heparan sulfate, an abundant proteoglycan present on mammalian cells, can mediate the interaction of LCMV with cell surfaces (05). Thus, like alpha-dystroglycan, heparan sulfate may contribute to LCMV infection of certain cells. Following engagement of LCMV with alpha-dystroglycan or heparan sulfate at cellular surfaces, viral entry occurs via endocytosis and fusion with the lysosomal glycoprotein CD164 (05).

Early studies with LCMV revealed that most tissues in mice are vulnerable to infection. However, the virus has been notably absent from muscle cells. It was assumed that muscle cells must lack the receptor for the virus. However, when it was later discovered that alpha-dystroglycan is the receptor for LCMV, and that skeletal muscle contains large quantities of alpha-dystroglycan, it became evident that there must be some other explanation for the uninfectability of muscle cells. It has been shown that myotubes are refractory to LCMV infection due to impaired cell entry. In particular, the surface glycoprotein on LCMV impairs penetration through the muscle cell membrane (42).

LCMV surface glycoproteins are being studied extensively due to their key role in receptor binding, leading to internalization and fusion of the virion with the cell membrane. LCMV utilizes two different envelope glycoproteins to bind to and invade cells. The first envelope glycoprotein is GP1, which LCMV uses to bind to the alpha-dystroglycan. The second envelope glycoprotein, GP2, then facilitates viral and host cell fusion, followed by internalization of LCMV into the host cell via endocytosis (66). Studies in cell cultures using recombinant LCMV with various N glycosylation mutants have revealed that N glycosylation of these glycoproteins is important in determining viral fitness and cell tropism. Mutations leading to deletion of N glycans in the LCMV glycoprotein provide an advantage to the virus for infection of neurons but a disadvantage for infection of macrophages. Due to effects on protein folding, N glycosylation may mask antibody binding sites, which may have important implications for development of an LCMV vaccine (11).

When fetal mice acquire LCMV vertically from their mothers, the virus persists within their neurons, where the virus can alter gene expression and lead to long-term specific behavioral deficits. Mice with life-long high viral loads exhibit impaired learning and memory. Specifically deficient is the acquisition phase of learning on a novel avoidance task (49). These learning and memory problems appear to be due to viral-induced interference with adult neurogenesis. In particular, persistent LCMV infection in mice substantially impairs the generation of neuroblasts from neuroprogenitor cells within the dentate gyrus and subventricular regions. This interference with neurogenesis is likely related to chronic upregulation of proinflammatory cytokines, which can impair cellular production (74). Whether LCMV persists in humans following congenital infection and whether LCMV infection can alter human neuronal gene expression, as it does in mice, are unknown.

Epidemiology

	• LCMV is a prevalent pathogen, is carried and transmitted by mice, and infects large numbers of humans world-wide.
	• Acquired LCMV infections occur most commonly in the fall and winter months, reflecting the times when humans cohabitate with mice.
	• Approximately 5% of all humans carry anti-LCMV antibodies, demonstrating prior exposure and infection.
	• The incidence of congenital LCMV infection is unknown but probably occurs far more often than is typically appreciated.

The incidence and prevalence of congenital LCMV infection are unknown. Although the published case reports of LCMV infection during pregnancy make it clear that LCMV can be a severe neuroteratogen, it is not known whether the profoundly affected infants described in the case reports represent the typical outcome of gestational LCMV infection or whether they represent only the most severely affected cases. No prospective epidemiological or clinical studies of congenital LCMV infection have been conducted. Information regarding the incidence and spectrum of LCMV-induced teratogenicity is further limited by the fact that LCMV is not one of the infectious agents for which infants with a suspected congenital infection are routinely checked. Therefore, it is possible that congenital LCMV infection, like many other congenital infections, produces a spectrum of pathologic effects that range from minimal to profound.

Although the incidence of gestational LCMV infection is unknown, it is known that LCMV is prevalent in the environment, has a great geographic range, and infects large numbers of humans. LCMV is endemic in wild mice throughout temperate regions (01) and probably occurs wherever the species Mus musculus, its natural reservoir, exists. Until recent years, LCMV had not been detected in Africa. However, Mus musculus has advanced and colonized in many areas in Africa. As these domestic mice have spread, so has the virus. In 2015, LCMV RNA was detected for the first time in Mus musculus within a country of Western Africa. Indeed, 13% of the Mus musculus mice were found to be infected with LCMV. A later study, in 2021, found that the seroprevalence for LCMV in humans in Gabon, Central Africa is 21.5%, and the LCMV RNA could be detected in several novel rodent species, including porcupines and shrews (78). These findings demonstrate that LCMV is emerging as a new threat to the people and native rodent species of Africa (62).

An epidemiologic study several decades ago demonstrated that 9% of the house mice in urban Baltimore are infected with LCMV and that significant clustering occurs where the prevalence is higher (27). A study examining the seroprevalence of LCMV in Colombia found that 10% of wild mice are seropositive for LCMV (23). This similar prevalence to the Baltimore study suggests that the LCMV infection rate among mice is relatively stable over time and geography, at least across the Americas.

However, mouse infection rates with LCMV may not be equivalent everywhere. One factor that may greatly increase local mouse infection rates with LCMV is the presence of illegal waste sites. In illegal waste sites, because of abundant food supplies and ideal shelters, rodents have optimal conditions to breed and survive. As a result, the densities of rodents are high, thus, facilitating the transmission of rodent-borne viral infections. The prevalence of LCMV infection among mice in waste sites may also be due to a change in mouse behavior. When food resources are abundant, male mice become more aggressive and are more likely to inflict bite wounds, thus, facilitating the horizontal transmission of viral infections. One study demonstrated that, within illegal waste sites, seroprevalence for LCMV in Mus musculus was greater than 47%, a rate that far exceeds the seroprevalence rates in natural habitats (33).

Serological studies have found that 4.7% of adults in Baltimore and 5.1% of healthy black women in Birmingham possess antibodies to LCMV, indicating prior exposure and infection (27; 73). A study in 2021 found similar seroprevalence rates in Croatia, with 6.1% seroprevalence in the general population and 3.9% in pregnant women (80). Together, the data suggest that congenital LCMV infection is an underdiagnosed disease and that the virus is responsible for more cases of congenital neurologic and vision dysfunction than has previously been recognized (43; 57; 07).

A study conducted in the United States found that the great majority of congenital LCMV infections occurred in either urban or rural settings and that very few occurred in suburban settings (19). This disproportionate weighting toward urban and rural dwellers over suburban dwellers likely reflects exposure to infected mice because women living in urban apartment buildings or near corn cribs and other rural outbuildings are more likely to be exposed to mice than women living in suburban single-family houses. In this sense, the incidence of congenital LCMV reflects health disparities among socioeconomic classes (65; 13).

Acquired LCMV infections can occur at any time of the year; however, most occur during the late autumn and winter months. This probably reflects seasonal variations in the cohabitation of humans with mice. During the cold months of autumn and winter, wild mice are driven indoors, carrying LCMV with them and increasing the likelihood of a human infection.

In the wake of the September 11, 2001 terrorist attacks on the United States, greater emphasis has been placed on the potential of bioterrorism. Along with the other arenaviruses, LCMV has been listed by the Centers for Disease Control as a Category A Priority Pathogen. LCMV ranks as a high-priority agent and as a risk to national security because it is easily disseminated, has the potential for major public health impact, and could induce public panic and social disruption (25).

Prevention

	• There is no vaccine to prevent LCMV infection.
	• People can minimize their risk of infection by avoiding exposure to wild mice and their secretions.
	• Because LCMV can be transmitted via organ transplant, care should be taken to ensure that organ donors are free of LCMV.

No vaccine exists to prevent LCMV infection; however, measures can be taken to reduce the risk of infection. Congenital LCMV infection will not occur unless a woman contracts a primary infection with LCMV during pregnancy. Rodents, especially house mice, are the principal reservoir of LCMV. Women can reduce their risk of contracting LCMV by minimizing their exposure to the secretions and excretions of mice. This can be accomplished most effectively by eliminating cohabitation with mice. Pregnant women should also avoid contact with pet rodents, especially mice and hamsters. Laboratory personnel who work with rodents have an increased risk of infection with LCMV. Pregnant women who work in animal care facilities or laboratories at research institutions should wear gloves, gowns, and face masks to avoid potential aerosolized or secreted LCMV.

Because congenitally infected mice can secrete large quantities of LCMV and remain essentially asymptomatic, LCMV may be rampant within animal colonies at research institutions, thus, putting laboratory workers, and especially pregnant women and their fetuses, at risk. Therefore, all animal colonies should be tested periodically for LCMV (34).

Acquisition of LCMV from solid organ transplantation represents a substantial risk to the life of the recipient. Donors with LCMV meningitis or encephalitis pose a clear risk for transmitting a fatal infection to recipients. Health care providers, transplant centers, and organ procurement organizations should be aware of the risks posed by LCMV and should consider LCMV in any potential donor with signs of aseptic meningitis but no identified infectious agent. The risks and benefits of offering and receiving organs from donors with possible LCMV infection should be carefully weighed (24).

Differential diagnosis

Confusing conditions

The principal items in the differential diagnosis of congenital LCMV infection are the other infectious pathogens that can cross the placenta and damage the developing fetus. These infectious agents are linked conceptually by the acronym "TORCHS" and include Toxoplasma gondii, rubella virus, cytomegalovirus, herpes simplex virus, and syphilis. Cytomegalovirus and toxoplasmosis are particularly difficult to differentiate from LCMV because infection with any of these three infectious agents can produce microcephaly, intracerebral mineralization, and chorioretinitis. Although clinical clues may aid in distinguishing one congenital infection from another, definitive identification of the causative infectious agent usually requires laboratory data, including cultures and serologic studies (20).

Symptomatic congenital cytomegalovirus infection is usually associated with several systemic signs that are not observed in congenital LCMV infection. These include hepatosplenomegaly, jaundice, anemia, intrauterine growth retardation, and a petechial or purpuric rash. Hearing deficits are common in infants infected with cytomegalovirus but are unusual in congenital LCMV infection. The diagnosis of congenital cytomegalovirus infection is best established by isolating the virus from urine or saliva within the first three weeks of life. Detection beyond this time point may reflect postnatal acquisition of the virus (20).

Of all of the congenital infections, toxoplasmosis most closely mimics congenital LCMV infection. Microencephaly, hydrocephalus, chorioretinitis, and intracranial calcifications are hallmarks of both congenital infections. Approximately 10% of newborns infected with Toxoplasma gondii will exhibit hepatosplenomegaly, jaundice, and rash (40). These systemic signs are usually absent in congenital LCMV infection. The two infections also tend to differ neuroradiographically. In cases of congenital toxoplasmosis, the intracranial mineralization tends to be diffuse within the brain parenchyma. In contrast, in congenital LCMV infection, the mineralizations are typically periventricular. Congenital infection with toxoplasmosis and LCMV are so clinically similar, however, that differentiating among them requires laboratory testing. The diagnosis of congenital toxoplasmosis can be established by serologic studies and confirmed by detecting the infectious organisms in tissues, blood, or cerebrospinal fluid.

Zika virus has emerged as a major pathogen worldwide, especially in the Americas. An arbovirus that is spread by the bite of mosquitoes, Zika can cause congenital infections that, like LCMV, can induce severe brain and retinal injuries. Zika is further similar to LCMV in that it is an intensely neurotropic virus that targets neuroprogenitor cells and tends to spare other fetal organs. Congenital Zika infection leads to microencephaly that is often even more severe than that observed with LCMV. The most severe form of microencephaly is referred to as fetal brain disruption sequence, in which the sutures overlap and there are scalp rugae. This condition is commonly induced by Zika, but rarely occurs with LCMV. Both Zika and LCMV can induce cerebral calcifications. However, in congenital Zika virus infection, the calcifications tend to occur at the gray-white matter junction, whereas in LCMV they are usually periventricular (53).

The incidence of congenital rubella syndrome has diminished since the institution of universal immunization, but the condition has not been eliminated and must be considered in any newborn with signs suggestive of a congenital infection. A woman contracting rubella during pregnancy typically has symptoms of sore throat, headache, fever, malaise, and myalgias. These symptoms of rubella closely resemble the usual symptoms of acquired LCMV infection. Congenital rubella syndrome, however, typically includes intrauterine growth retardation, cataracts, congenital heart disease, hepatosplenomegaly, jaundice, purpuric rash, and sensorineural hearing loss, which are systemic signs not typically present in congenital LCMV infection. Congenital rubella syndrome can be confirmed by isolating rubella virus from urine, cerebrospinal fluid, or blood. Detecting rubella-specific IgM or persistently high levels of rubella-specific IgG in an infant's sera also strongly supports the diagnosis of congenital rubella infection.

Herpes simplex viruses types 1 and 2 are prevalent viruses that commonly cause substantial damage to newborn infants. Like LCMV, infection with Herpes simplex virus can cause chorioretinitis and encephalitis during the newborn period. However, most cases of neonatal Herpes simplex virus infection are acquired during the intrapartum or early postnatal periods, unlike congenital LCMV infection, which occurs prenatally. Thus, unlike cases of congenital LCMV, most infants with Herpes simplex virus will not have microcephaly or hydrocephalus at birth. In addition, many neonates with the infection will exhibit multiple systemic signs, including vesicular skin lesions, conjunctivitis, hepatic dysfunction, pneumonitis, and disseminated intravascular coagulopathy. These systemic signs are typically absent in congenital LCMV infection. The diagnosis of Herpes simplex virus infection can be confirmed by polymerase chain reaction or by isolating the virus from the oropharynx, cerebrospinal fluid, skin vesicles, or conjunctiva.

Congenital syphilis, the disease caused by infection of the fetus with the spirochete Treponema pallidum, is an important cause of developmental brain injury worldwide, despite rigorous public health measures and effective antibiotic therapy. Like congenital LCMV, congenital syphilis can induce retinopathy, meningo-encephalitis, developmental delay, and seizure disorders. However, congenital syphilis can usually be recognized by the physical stigmata accompanying the infection. Features of congenital syphilis in the neonate reflect disseminated infection and include low birth weight, skin rash (particularly on the palms and soles), lymphadenopathy, hepatosplenomegaly, jaundice, persistent rhinitis, and periostitis or osteochondritis. The osseous abnormalities, which are the most consistent clinical features of congenital syphilis, may inhibit limb movement (pseudoparalysis) and are absent in congenital LCMV infection. Infants with suspected congenital syphilis require a thorough evaluation that should include radiography of long bones, cerebrospinal fluid examination, serologic assays, and histopathologic examination (with dark field microscopy) of the umbilical cord, placenta, and skin lesions.

The differential diagnosis of congenital LCMV infection also includes several noninfectious entities. Chromosomal abnormalities are prominent causes of microencephaly. However, abnormalities in the structure or number of chromosomes commonly induce dysmorphic features (especially of the hands, feet, and facies) or structural abnormalities (especially of the heart or genitourinary system) that are not observed in congenital LCMV infection.

Several genetic disorders can mimic congenital LCMV infection (68; 37). In particular, Aicardi-Goutières syndrome is an autosomal recessive disorder that often presents as neonatal encephalopathy and intracranial calcifications (67). However, its progressive course and identifiable mutations in the TREX1 and RNASEH2 genes distinguish it from congenital LCMV infection.

A second genetic disorder that mimics congenital LCMV is pseudo-TORCH syndrome (63; 47). In this autosomal recessive disorder, infants have many of the classic features of the common congenital infections that gave rise to the TORCH acronym (toxoplasmosis, other infections, rubella, cytomegalovirus, herpes viruses). However, in pseudo-TORCH syndrome, no serological or microbiological evidence of a congenital infection is ever identified. Congenital LCMV infection can be distinguished from pseudo-TORCH syndrome in several ways. First, most mothers of infants with congenital LCMV infection have a history of exposure to wild mice and experience a definite “flu-like” illness during the pregnancy; these historical factors are typically absent in pseudo-TORCH syndrome. Most importantly, chorioretinitis is present in all cases of congenital LCMV infection and absent in cases of pseudo-TORCH syndrome (12).

One other genetic disorder, Aicardi syndrome, can closely mimic congenital LCMV infection (82; 83; 45). Aicardi syndrome causes lacunar retinopathy and infantile seizures, and is usually accompanied by microencephaly and developmental delay. In addition, Aicardi syndrome can induce polymicrogyria or pachygyria and ventriculomegaly. All of these features of Aicardi syndrome are likewise commonly observed in congenital LCMV. However, agenesis of the corpus callosum and vertebral anomalies, which are hallmarks of Aicardi syndrome, are not clinical features of congenital LCMV infection. Nevertheless, Aicardi syndrome shares so many features in common with congenital LCMV infection that some authors have suggested that all children suspected of Aicardi syndrome should undergo LCMV serology testing (45).

Finally, infants with tuberous sclerosis, a genetic disorder with an autosomal dominant inheritance pattern and a high spontaneous mutation rate, may have intracranial calcifications and seizures (especially infantile spasms), which are also clinical features of congenital LCMV infection. However, unlike congenital LCMV infection, infants with tuberous sclerosis will often have affected family members and will not typically have microcephaly or hydrocephalus (though they may develop hydrocephalus later in life as a result of periventricular brain tumors).

Diagnostic workup

	• Acute LCMV infections can be diagnosed by isolation of the virus from the infected host, but this is technically difficult and has a high false-negative rate.
	• LCMV infections can be diagnosed molecularly by PCR, but the virus and its nucleic acids may be cleared from infants prior to birth.
	• Congenital LCMV is most commonly and reliably diagnosed serologically.

Acute human LCMV infections can be diagnosed by isolation of the virus from cerebrospinal fluid. However, by the time of birth, a baby prenatally infected with LCMV may no longer harbor the virus. Thus, congenital LCMV infection is usually diagnosed by means of serologic testing. The immunofluorescent antibody test detects both IgM and IgG and has greater sensitivity than the more widely available complement fixation method (52). The immunofluorescent antibody test is commercially available, and its specificity and sensitivity make it an acceptable diagnostic tool. An even more sensitive test for the detection of congenital LCMV infection is the ELISA, which measures titers of LCMV IgG and IgM and is performed at the Centers for Disease Control and Prevention.

Although serology may be utilized to confirm congenital LCMV infection, such serological testing may be unavailable, or healthcare providers may neglect to consider congenital LCMV infection. In these situations, knowledge of prenatal neuroimaging findings consistent with congenital LCMV infection may enhance its detection and diagnosis. A case of congenital LCMV was detected following visualization of several abnormal head ultrasound findings, including dysmorphic caudate nuclei with calcifications, enlarged subarachnoid fluid spaces, and cerebellar hypoplasia (77). Likewise, several cases of congenital LCMV have been detected postnatally by head ultrasound. In each of these cases, maternal history was consistent with rodent exposure, and serological data confirmed prenatal LCMV infection (69).

Polymerase chain reaction has been utilized as a means of detecting LCMV RNA in an infected infant (35). The use of polymerase chain reaction offers exciting possibilities for detection of LCMV infection. Polymerase chain reaction for the detection of viral genes is both highly specific and sensitive. Indeed, real-time polymerase chain reaction can detect genomic sequences reliably in CSF, even when the viral concentration is less than 10 live viruses per milliliter (30). However, LCMV does not induce persistent infections in humans, and the time course of viral clearance from an infected human fetus is unknown. A fetus may sustain substantial brain damage from LCMV but effectively clear the virus and have no LCMV RNA to be detected by polymerase chain reaction in the postnatal period. Thus, in many cases, it would be most ideal to test for LCMV during the prenatal period. In 2017, the first case was published describing the use of polymerase chain reaction to prenatally diagnose a fetus infected with LCMV (32). The mother, who had been exposed to mice, had suffered from a flu-like illness during the 16th week of pregnancy. Subsequent prenatal ultrasounds revealed fetal ventriculomegaly and hyperechogenicity of cerebral parenchyma. Amniocentesis at 24 weeks gestation produced amniotic fluid with negative polymerase chain reaction screening for the common “TORCH” infections but was positive for LCMV. Thus, polymerase chain reaction can be used to diagnose congenital LCMV infection prenatally.

Management

	• There is no specific treatment for people infected with LCMV.
	• No antiviral agent has been shown to prevent infection with LCMV or to impair its replication in patients.
	• Steroids may improve the symptoms of acute LCMV infection and hasten recovery.

There is no specific treatment for LCMV infection. An effective antiviral therapy for LCMV infection has not yet been developed. Ribavirin has had some mixed success in the treatment of severe infections but is limited to off-label use and is associated with substantial toxicity. Ribavirin displays a dual mutagenic and inhibitory activity on LCMV that can be relevant to future treatment designs (61). Another promising antiviral compound is favipiravir, a pyrazine derivative with broad antiviral activity against RNA viruses. By disrupting early stages of viral replication, favipiravir has robust antiviral activity against arenaviruses (56). In addition, unlike ribavirin, favipiravir has little cellular toxicity. However, to date, favipiravir’s antiviral effects against LCMV have been tested only in cell culture. Whether favipiravir could protect animals or humans infected with LCMV is unknown.

Valproic acid, a medication commonly used to treat epileptic seizures, has also shown promise in controlling LCMV infection by inhibiting budding and release of viral particles. To date, the effect of valproic acid on LCMV infection has been studied only in culture, but the findings suggest that therapeutic doses used to treat epilepsy could produce antiviral effects (79).

One study, conducted in vitro, has shown that arbidol, an approved influenza antiviral, when combined with other approved drugs, including aripiprazole, amodiaquine, sertraline, and niclosamide, can inhibit the infection of cells by arenaviruses, including LCMV. This study provides proof of concept that combinations of approved drugs could act synergistically to inhibit LCMV infections (41).

Because virus-infected cells have high metabolic demands to produce viral particles, the hypothesis has arisen that glucose deprivation might slow viral propagation. A study conducted in vitro investigating the life cycle of LCMV found that glucose supply and utilization have no effect on viral propagation (04). However, the addition of 2-Deoxy-D-glucose, a glycolytic inhibitor, to the medium containing LCMV infected cells suppressed N-glycosylation of viral glycoproteins and inhibited viral propagation. This finding reveals glycoproteins as potential targets for future anti-LCMV therapies.

Because most acquired LCMV infections have relatively mild symptoms that resolve spontaneously, no treatment is necessary. In cases in which LCMV produces more severe symptoms of meningitis or encephalitis, a course of steroids may substantially improve the symptoms and hasten recovery (71).

Children with hydrocephalus due to congenital LCMV infection often require placement of a ventriculoperitoneal shunt during infancy. Seizures often begin during early postnatal life, are difficult to control, and require administration of multiple antiepileptic medications. The mental retardation induced by congenital LCMV infection is often profound. In most cases, affected children should be referred for education intervention during early life. The spasticity accompanying congenital LCMV infection is often severe. Although physical therapy can help to maintain range of motion and minimize painful spasms and contractures, implantation of a baclofen pump is often necessary and helpful.

In many cases, identifying the source of the LCMV infection for a patient is important in order to take potential action against the offending rodent infestation and to minimize the risk of infection to others. This often involves trapping mice in homes and businesses and confirming the LCMV infection through necropsy, serology, and tissue testing of the trapped mice. However, trapping mice can sometimes be problematic and time-consuming. One report has demonstrated that the source of LCMV can sometimes be confirmed by testing fecal pellets of rodents by polymerase chain reaction (75).

Media

References

01: Ambrosio AM, Feuillade MR, Gamboa GS, Maiztegui JI. Prevalence of lymphocytic choriomeningitis virus infection in a human population of Argentina. Amer J Trop Med Hyg 1994;50:381-6. PMID 8147496
02: Ansari N, Demmler-Harrison G, Coats DK, Paysse EA. Severe congenital chorioretinitis caused by congenital lymphocytic choriomeningitis virus infection. Am J Ophthalmol Case Rep 2021;22:101094. PMID 33981914
03: Armstrong C, Lillie RD. Experimental lymphocytic choriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1933 St. Louis encephalitis epidemic. Public Health Rep 1934;49:1019-22.
04: Badurova L, Polčicová K, Omasta B, Ovečková I, Kocianová E, Tomášková J. 2-Deoxy-D-glucose inhibits lymphocytic choriomeningitis virus propagation by targeting glycoprotein N-glycosylation. Virol J 2023;20(1):108. PMID 37259080
05: Bakkers MJG, Moon-Walker A, Herlo R, et al. CD164 is a host factor for lymphocytic choriomeningitis virus entry. Proc Natl Acad Sci USA 2022;119(10):e2119676119. PMID 35235462
06: Barton LL, Budd SC, Morfitt WS, et al. Congenital lymphocytic choriomeningitis virus infection in twins. Pediatr Infect Dis J 1993;12:942-6. PMID 8265286
07: Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis 2001;33:370-4. PMID 11438904
08: Barton LL, Peters CJ, Ksiazek TG. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. Emerg Inf Dis 1995;1:152-3. PMID 8903188
09: Biggar R, Woodall J, Walter P, Haughie G. Lymphocytic choriomeningitis outbreak associated with pet hamsters: fifty seven cases from New York state. JAMA 1975;232:494. PMID 1173141
10: Bodewes R, Kik MJ, Raj VS, et al. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. J Gen Virol 2013;94(Pt 6):1206-10. PMID 23468423
11: Bonhomme CJ, Knopp KA, Bederka LH, Angelini MM, Buchmeier MJ. LCMV glycosylation modulates viral fitness and cell tropism. PLoS One 2013;8:e53273. PMID 23308183
12: Bonthius DJ. Diagnosed cases of congenital LCMV infection: tip of the iceberg. Ann Neurol 2008;64:356.
13: Bonthius DJ. Lymphocytic choriomeningitis virus injures the developing brain: effects and mechanisms. Pediatr Res 2024;95(2):551-7. PMID 38182822
14: Bonthius DJ, Karacay B. Meningitis and encephalitis in children: an update. Neurol Clin 2002;20:1013-38. PMID 12616679
15: Bonthius DJ, Mahoney JC, Buchmeier MJ, Taggard DA. Critical role for glial cells in the propagation and spread of lymphocytic choriomeningitis virus in the developing rat brain. J Virol 2002;76(13):6618-35. PMID 12050375
16: Bonthius DJ, Nichols B, Harb H, Mahoney J, Karacay B. Lymphocytic choriomeningitis virus infection of the developing brain: critical role of host age. Ann Neurol 2007a;62:356-74. PMID 17696127
17: Bonthius DJ, Perlman S. Congenital viral infections of the brain: lessons learned from lymphocytic choriomeningitis virus in the neonatal rat. PLoS Pathogens 2007;3:1541-1550. Also available at www.plospathogens.org. PMID 18052527
18: Bonthius DJ, Taggard D, Mahoney J, Assouline J. The topography of lymphocytic choriomeningitis virus (LCMV) and of its putative receptor in the developing rat brain. J Neurovirol 2000;6:437.
19: Bonthius DJ, Wright R, Tseng B, et al. Congenital lymphocytic choriomeningitis virus infection: spectrum of disease. Ann Neurol 2007b;62:347-55. PMID 17557350
20: Boucoiran I, Kakkar F, Renaud C. Maternal infections. In: Gallagher A, Bulteau C, Cohen D, Michaud JL, editors. Handbook of Clinical Neurology. Neurocognitive Development: Normative Development. Volume 173, 3rd series. Amsterdam: Elsevier, 2020:401-22.
21: Buchmeier MJ, Zajac AJ. Lymphocytic choriomeningitis virus. In: Ahmed R, Chen I, editors. Persistent viral infections. New York: Wiley, 1999:575-605.
22: Cao W, Henry MD, Borrow P, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus. Science 1998;282:2079-81. PMID 9851928
23: Castellar A, Guevara M, Rodas JD, et al. First evidence of lymphocytic choriomeningitis virus (arenavirus) infection in Mus musculus rodents captured in the urban area of the municipality of Sincelejo, Sucre, Colombia. Biomedica 2017;37(0):75-85. PMID 28527269
24: Centers for Disease Control and Prevention. Lymphocytic choriomeningitis virus transmitted through solid organ transplantation---Massachusetts, 2008. MMWR Morb Mortal Wkly Rep 2008;57(29):799-801. PMID 18650788
25: Centers for Disease Control and Prevention. CDC Public Health Emergency Preparedness and Response Web site. Accessed October 20, 2020.
26: Chesney PJ, Katcher ML, Nelson DB, Horowitz SD. CSF eosinophilia and chronic lymphocytic choriomeningitis virus meningitis. J Pediatr 1979;94:750-2. PMID 448483
27: Childs JE, Glass GE, Korch GW, Ksiazek TG, Leduc JW. Lymphocytic choriomeningitis virus infection and house mouse (mus musculus) distribution in urban Baltimore. Amer J Trop Med Hyg 1992;47:27-34. PMID 1636880
28: Christensen JE, Simonsen S, Fenger C, et al. Fulminant lymphocytic choriomeningitis virus-induced inflammation of the CNS involves a cytokine-chemokine-cytokine-chemokine cascade. J Immunol 2009;182:1079-87. PMID 19124751
29: Christiaansen AF, Schmidt ME, Hartwig SM, Varga SM. Host genetics play a critical role in controlling CD8 T cell function and lethal immunopathology during chronic viral infection. PLoS Pathog 2017;13(7):e1006498. PMID 28715493
30: Cordey S, Sahli R, Moraz ML, et al. Analytical validation of a lymphocytic choriomeningitis virus real-time RT-PCR assay. J Virol Methods 2011;177(1):118-22. PMID 21763351
31: Delaine M, Weingertner A, Nougairede A, et al. Microcephaly caused by lymphocytic choriomeningitis virus. Emerg Infect Dis 2017a;23(9):1584-50. PMID 28820372
32: Delaine M, Weingertner AS, Nougairede A, et al. Congenital lymphocytic choriomeningitis virus: a case of prenatal diagnosis. J Ultrasound Med 2018;37(3):804-6. PMID 28858375
33: Duh D, Hasic S, Buzan E. The impact of illegal waste sites on a transmission of zoonotic viruses. Virology J 2017;14:134. PMID 28728557
34: Dykewicz CA, Dato VM, Fisher-Hoch SP. Lymphocytic choriomeningitis outbreak associated with nude mice in a research institute. JAMA 1992;267:1349-53. PMID 1740856
35: Enders G, Varho-Gobel M, Lohler J, Terletskain-Ladwig E, Eggers, M. Congenital lymphocytic choriomeningitis virus infection: an underdiagnosed disease. Ped Infect Dis J 1999;18:652-5. PMID 10440448
36: Enninga EAL, Theiler RN. Lymphocytic choriomeningitis virus infection demonstrates higher replicative capacity and decreased antiviral response in the first-trimester placenta. J Immunol Res 2019;2019:7375217. PMID 30882005
37: Farmer M, Sebire G. Genetic mimics of congenital LCMV encephalitis. Annals Neurol 2008;64(3):353-5. PMID 18409198
38: Fischer SA, Graham MB, Kuehnert M, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. New Engl J Med 2006;354:2235-49. PMID 16723615
39: Folk S, Steinbecker S, Windmeyer J, et al. Lymphocytic choriomeningitis with severe manifestations, Missouri, USA. Emerg Infect Dis 2011;17(10):1973-4. PMID 22000392
40: Hampton MM. Congenital toxoplasmosis: a review. Neonatl Netw 2015;34(5):274-8. PMID 26802827
41: Herring S, Oda JM, Wagoner J, et al. Inhibition of arenaviruses by combinations of orally available approved drugs. Antimicrob Agents Chemother 2021;65:e01146-20. PMID 33468464
42: Iwasaki M, Urata S, Cho Y, Ngo N, de la Torre JC. Cell entry of lymphocytic choriomeningitis virus is restricted in myotubes. Virology 2014;458-9:22-32. PMID 24928036
43: Jahrling PB, Peters CJ. Lymphocytic choriomeningitis virus: a neglected pathogen of man. Arch Pathol Lab Med 1992;116:486-8. PMID 1316111
44: Kim YC, Ahn JH, Jin H, et al. Immaturity of immune cells around the dural venous sinuses contributes to viral meningoencephalitis in neonates. Sci Immunol 2023;8(88):1-17. PMID 37801517
45: Kinori M, Schwartzstein J, Zeid JL, Kurup SP, Mets MB. Congenital lymphocytic choriomeningitis virus – an underdiagnosed fetal teratogen. J AAPOS 2018;22(1):79-81. PMID 29274373
46: Klein H, Rabe GK, Karacay B, Bonthius DJ. T-cells underlie some, but not all, of the cerebellar pathology in a neonatal rat model of congenital lymphocytic choriomeningitis virus infection. J Neuropathol Exp Neurol 2016;75(11):1031-47. PMID 27667772
47: Kniffen CL. Pseudo-TORCH syndrome 1; PTORCH1. OMIM #251290. https://www.omim.org/entry/251290. Accessed October 21, 2020.
48: Komrower GM, Williams BL, Stones PB. Lymphocytic choriomeningitis in the newborn. Probable transplacental infection. Lancet 1955;1:697-8. PMID 14354972
49: Kunz S, Rojek JM, Roberts AJ, McGavern DB, Oldstone MB, de la Torre JC. Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus. J Virol 2006;80:9082-92. PMID 16940520
50: Larsen PD, Chartrand SA, Tomashek KM, Hauser LG, Ksiazek TG. Hydrocephalus complicating lymphocytic choriomeningitis virus infection. Ped Infect Dis J 1993;12:528-31. PMID 8345985
51: Larsen PD, Wright R. Early clinical manifestations and long-term outcome in children with symptomatic congenital lymphocytic choriomeningitis virus infection. Neurology 2001;56:A39-40. Abstract.
52: Lehmann-Grube F, Kallay M, Ibscher B, Schwartz R. Serologic diagnosis of human infections with lymphocytic choriomeningitis virus: comparative evaluation of seven methods. J Med Virol 1979;4:125-36. PMID 385806
53: Levine D, Jani JC, Castro-Aragon I, Cannie M. How does imaging of congenital Zika compare with imaging of other TORCH infections? Radiology 2017;285(3):744-61. PMID 29155634
54: Lewis JM, Utz JP. Orchitis, parotitis and meningoencephalitis due to lymphocytic choriomeningitis virus. N Engl J Med 1961;265:776-80. PMID 14464883
55: McAfee MS, Huynh TP, Johnson JL, Jacobs BL, Blattman JN. Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. Virology 2015;484:153-62. PMID 26099694
56: Mendenhall M, Russell A, Juelich T, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 2011;55(2):782-7. PMID 21115797
57: Mets MB, Barton LL, Khan AS, Ksiazek TG. Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am J Ophthalmol 2000;130:209-15. PMID 11004296
58: Meyer HM, Johnson RT, Crawford IP, et al. Central nervous system syndromes of "vital" etiology. A study of 713 cases. Am J Med 1960;29:334. PMID 13794743
59: Monjan AA, Cole GA, Nathanson N. Pathogenesis of LCM disease in the rat. In: Lehmann F, editor. Lymphocytic choriomeningitis virus and other arenaviruses. Springer-Verlag, 1973:195-206.
60: Monjan AA, Gilden DH, Cole GA, Nathanson N. Cerebellar hypoplasia in neonatal rats caused by lymphocytic choriomeningitis virus. Science 1971;171:194-6. PMID 4992415
61: Moreno H, Grande-Perez A, Domingo E, Martin V. Arenaviruses and lethal mutagenesis: prospects for new ribavirin-based interventions. Viruses 2012;4:2786-805. PMID 23202505
62: N’Dilimabaka N, Berthet N, Rougeron V, et al. Evidence of lymphocytic choriomeningitis virus (LCMV) in domestic mice in Gabon: risk of emergence of LCMV encephalitis in central Africa. J Virol 2015;89(2):1456-60. PMID 25378495
63: O'Driscoll MC, Daly SB, Urquhart JE, et al. Recessive mutations in the gene encoding the tight junction protein occludin cause band-like calcification with simplified gyration and polymicrogyria. Am J Hum Genet 2010;87(3):354-64. PMID 20727516
64: Oldstone MB, Campbell KP. Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 2011;411(2):170-9. PMID 21185048
65: Olivieri NR, Othman L, Flannery DD, Gordon SM. Transmission, seroprevalence, and maternal-fetal impact of lymphocytic choriomeningitis virus. Pediatr Res 2023;95(2):456-3. PMID 37857846
66: Olivieri NR, Othman L, Gordon SM. Health disparities revealed in a case of congenital LCMV. Pediatr Res 2024;95(2):579-80. PMID 37542168
67: Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Amer J Hum Genet 2007;81:713-25. PMID 17846997
68: Sanchis A, Cervero L, Bataller A, et al. Genetic syndromes mimic congenital infections. J Pediatr 2005;146:701-5. PMID 15870678
69: Sharma K, Singhapakdi K, Maertens P. Echoencephalography of encephalopathy due to congenital lymphocytic choriomeningitis virus. J Neuroimaging 2022;32(3):412-9. PMID 35297514
70: Smelt SC, Borrow P, Kunz S, et al. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virology 2001;75:448-57. PMID 11119613
71: Souders HT, Byler D, Marupudi N, Patel R, McSherry G. Protracted symptoms in lymphocytic choriomeningitis: a case report. J Child Neurol 2015;30(5):644-7. PMID 24736119
72: Spiropoulou CF, Kunz S, Rollin PE, Campbell KP, Oldstone MB. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J Virol 2002;76:5140-6. PMID 11967329
73: Stephensen CB, Blount SR, Lanford RE, et al. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. cities. J Med Virol 1992;38:27-31. PMID 1402829
74: Sun T, Vasek MJ, Klein RS. Congenitally acquired persistent lymphocytic choriomeningitis viral infection reduces neuronal progenitor pools in the adult hippocampus and subventricular zone. PLoS One 2014;9(5):e96442. PMID 24802239
75: Talley P, Holzbauer S, Smith K, Pomputius W. Notes from the field: lymphocytic choriomeningitis virus meningoencephalitis from a household rodent infestation – Minnesota, 2015. MMWR Morb Mortal Wkly Rep 2016;65(9):248-9. PMID 26963688
76: Teijaro JR, Ng Cherie, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013;340(6129):207-11. PMID 23580529
77: Tevaearai F, Moser L, Pomar L. Prenatal diagnosis of congenital lymphocytic choriomeningitis virus infection: a case report. Viruses 2022;14(11):2586. PMID 36423195
78: Ushijima Y, Abe H, Ozeki T, et al. Identification of potential novel hosts and the risk of infection with lymphocytic choriomeningitis virus in humans in Gabon, Central Africa. Int J Infect Dis 2021;105:452-9. PMID 33667697
79: Vazquez-Calvo A, Martin-Acebes MA, Saiz JC, Ngo N, Sobrino F, de la Torre JC. Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid. Antiviral Res 2013;99(2):172-9. PMID 23735299
80: Vilibic-Cavlek T, Oreski T, Korva M, et al. Prevalence and risk factors for lymphocytic choriomeningitis infection in continental Croatian regions. Trop Med Infect Dis 2021;6:67. PMID 33947040
81: Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013;340(6129):202-7. PMID 23580528
82: Wright R, Johnson D, Neumann M, et al. Congenital lymphocytic choriomeningitis virus syndrome: A disease that mimics congenital toxoplasmosis or cytomegalovirus infection. Pediatrics 1997;100:1-6. PMID 9200383
83: Yu JT, Culican SM, Tychsen L. Aicardi-like chorioretinitis and maldevelopment of the corpus callosum in congenital lymphocytic choriomeningitis virus. J AAPOS 2006;10(1):58-60. PMID 16527682
84: Zinkernagel MS, Bolinger B, Krebs P, Onder L, Miller S, Ludewig B. Immunopathological basis of lymphocytic choriomeningitis virus-induced chorioretinitis and keratitis. J Virol 2009;83(1):159-66. PMID 18945766

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Daniel J Bonthius MD PhD

Dr. Bonthius of Atrium Health/Levine Children's Hospital has no relevant financial relationships to disclose.
See Profile
Richard McCormick MD

Dr. McCormick of Atrium Health in Charlotte, NC, has no relevant financial relationships to disclose.
See Profile

Editor

Bernard L Maria MD

Dr. Maria of Thomas Jefferson University has no relevant financial relationships to disclose.
See Profile

Former Authors

Jose Assouline MD
Nancy E Bonthius PharmD
Bahri Karacay PhD
Taylor Jerman MD
Hannah Klein de Licona BS
Glenda Rabe MD
Himali Jayakody MAAB
Jeffrey M Plume PhD
Dylan Todd MD
Daniel Bonthius Jr BS
Ryan M Bonthius BS
Vien Le

Patient Profile

Age range of presentation: 0 month to 5 years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: Infants of mothers living in inner city dwellings, in trailer parks, and on farms where wild mice are plentiful are most susceptible.
Occupation groups selectively affected: Women who work in research laboratories that include experimental mouse colonies are at increased risk to contract acute LCMV infection and to give birth to a baby with congenital LCMV.

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Congenital lymphocytic choriomeningitis virus infection

Associated Disorders

Noncommunicating hydrocephalus

Differential Diagnosis

other infectious pathogens
congenital toxoplasmosis
congenital rubella virus
cytomegalovirus
herpes simplex virus
- congenital syphilis
- hepatosplenomegaly
- jaundice
- anemia
- intrauterine growth
- petechial or purpuric rash
- brain parenchyma
- vesicular skin lesions
- conjunctivitis
- hepatic dysfunction
- pneumonitis
- disseminated intravascular coagulopathy
- low birth rate
- lymphadenopathy
- hepatosplenomegaly
- persistent rhinitis
- periostitis
- osteochondritis
- chromosomal abnormalities
- Aicardi syndrome
- agenesis of the corpus callosum
- vertebral anomalies
- tuberous sclerosis

Also Relevant

Neurologic complications of vaccination
Viral hemorrhagic fevers: neurologic complications
Viral meningitis

Congenital lymphocytic choriomeningitis virus infection

Congenital lymphocytic choriomeningitis virus infection

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Table 1. Titers for Lymphocytic Choriomeningitis Virus Infection

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Prion diseases

Rabies

Malaria

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Breath-holding spells

Congenital lymphocytic choriomeningitis virus infection

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Table 1. Titers for Lymphocytic Choriomeningitis Virus Infection

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Prion diseases

Rabies

Malaria

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Breath-holding spells

This is an article preview.
Start a Free Account
to access the full version.